Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease

Gastroenterology

Volumn 145, Issue 4, 2013, Pages

  Panés, Julián ^a,b   López Sanromán, Antonio ^c   Bermejo, Fernando ^d   García Sánchez, Valle ^e   Esteve, Maria ^b,f   Torres, Yolanda ^g   Domènech, Eugeni ^b,h   Piqueras, Marta ⁱ   Gomez García, María ^j   Gutiérrez, Ana ^b,k   Taxonera, Carlos ^l   Sans, Miquel ^a,b,m  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g San Juan de Dios Hospital   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ Brain   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^m CENTRO MÉDICO TEKNON   (Spain)

more..

Author keywords

AZTEC Study Inflammatory Bowel Diseases Treatment Corticosteroids

Indexed keywords

AZATHIOPRINE; BUDESONIDE; PLACEBO; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REMISSION; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84884411282     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.009     Document Type: Article

References (27)

1. L. Peyrin-Biroulet, E.V. Loftus Jr., and J.F. Colombel The natural history of adult Crohn's disease in population-based cohorts Am J Gastroenterol 105 2010 289 297
2. J. Markowitz, K. Grancher, and N. Kohn A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology 119 2000 895 902
3. N.J. Talley, M.T. Abreu, and J.P. Achkar An evidence-based systematic review on medical therapies for inflammatory bowel disease Am J Gastroenterol 106 Suppl 1 2011 S2 S25
4. G. Van Assche, A. Dignass, and J. Panés The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis J Crohns Colitis 4 2010 7 27
5. J. Cosnes, I. Nion-Larmurier, and L. Beaugerie Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery Gut 54 2005 237 241
6. W.R. Best, J.M. Becktel, and J.W. Singleton Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study Gastroenterology 70 1976 439 444
7. E.J. Irvine, B. Feagan, and J. Rochon Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group Gastroenterology 106 1994 287 296
8. P. Rutgeerts, R. Lofberg, and H. Malchow A comparison of budesonide with prednisolone for active Crohn's disease N Engl J Med 331 1994 842 845
9. M.A. Proschan, K.K.G. Lan, and J.T. Wittes Statistical monitoring of clinical trials: a unified approach 2006 Springer New York, NY
10. L. Beaugerie, P. Seksik, and I. Nion-Larmurier Predictors of Crohn's disease Gastroenterology 130 2006 650 656
11. I.C. Solberg, M.H. Vatn, and O. Hoie Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study Clin Gastroenterol Hepatol 5 2007 1430 1438
12. J. Cosnes, A. Bourrier, and Y. Bouhnik Accelerated step-care therapy with early azathioprine vs. conventional step-care therapy in Crohn's disease. A randomized study Gastroenterology 142 2012 S161
13. C.G. Sauer, and S. Kugathasan Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD Med Clin North Am 94 2010 35 52
14. D.A. Schoenfeld Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments Crit Care 9 2005 34 36
15. D.C. Pearson, G.R. May, and G. Fick Azathioprine for maintaining remission of Crohn's disease Cochrane Database Syst Rev 2000 CD000067
16. D.C. Pearson, G.R. May, and G.H. Fick Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis Ann Intern Med 123 1995 132 142
17. K.J. Khan, M.C. Dubinsky, and A.C. Ford Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis Am J Gastroenterol 106 2011 630 642
18. D.P. O'Donoghue, A.M. Dawson, and J. Powell-Tuck Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease Lancet 2 1978 955 957
19. S. Candy, J. Wright, and M. Gerber A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
20. J.L. Rosenberg, A.J. Wall, and B. Levin A controlled trial of azathioprine in the management of chronic ulcerative colitis Gastroenterology 69 1975 96 99
21. R.W. Summers, D.M. Switz, and J.T. Sessions Jr. National Cooperative Crohn's Disease Study: results of drug treatment Gastroenterology 77 1979 847 869
22. J.M. Willoughby, J. Beckett, and P.J. Kumar Controlled trial of azathioprine in Crohn's disease Lancet 2 1971 944 947
23. M. Veny, M. Esteller, and E. Ricart Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients Aliment Pharmacol Ther 31 2010 561 572
24. W.J. Sandborn, B.G. Feagan, and R.N. Fedorak A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
25. D.H. Present, S.J. Meltzer, and M.P. Krumholz 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity Ann Intern Med 111 1989 641 649
26. S.B. Hanauer, B.I. Korelitz, and P. Rutgeerts Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial Gastroenterology 127 2004 723 729
27. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395